Early detection of the disease is essential for being able to conduct clinical trials of treatments in the early stages, before there is major damage. In a recent publication Josef Pannee and co-authors, including Ingrid Zegers from JRC-IRMM describe a candidate mass-spectrometry-based reference method for the peptides Aβ38, Aβ40 and Aβ42.
One of the important points in the paper is that they can show that the clinical significance of the results obtained by the candidate reference method is as good as those obtained with immunoassays.
Read more in: J. Pannee et al.: "A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's Disease patients and healthy controls" http://dx.doi.org/10.3233/JAD-2012-121471